Quantcast

Latest MD Biosciences Stories

2014-04-14 23:06:18

MD Biosciences enters into an agreement with Janssen Research & Development, LLC to screen an extensive library of compounds with its proprietary Senerga® Phenotypic Screening Platform. Senerga®PSP is based on three matrices covering pathways related to inflammatory, metabolic, cardiovascular, and CNS diseases in addition to delivering preliminary toxicology data. St Paul, MN (PRWEB) April 14, 2014 MD Biosciences announces that it has entered into a research agreement with...

2013-09-25 23:25:37

A large animal model of post-operative pain (POP) that provides greater translational relevance for the evaluation of local treatments of POP compared with existing rodent models of incisional pain. St Paul, MN (PRWEB) September 25, 2013 MD Biosciences article "Characterization of a porcine model of post-operative pain" is published in the September 2013 issue of European Journal of Pain. Dr Sigal Meilin, lead neuroscientist and research director at MD Biosciences along with...

2013-08-08 23:17:34

MD Biosciences focuses on rapid and cost effective models of psoriasis involving the IL-23/Th17 axis in order to provide companies alternatives to complex and cost prohibitive xenotransplantation models for screening. With the earlier launch of the IMQ model and now the IL-23 psoriasis model, MD Biosciences offers a range of rapid models for dermal conditions such as dermatitis and psoriasis. St Paul, MN (PRWEB) August 08, 2013 Recent psoriasis research has focused extensively on the...

2013-06-27 23:20:13

Expansion provides increased capacity, ability to add new models as well as continue the development of new methods and biomarkers that bring clinical insight to the nonclinical drug development phase. St Paul, MN (PRWEB) June 27, 2013 MD Biosciences, a global preclinical contract research organization (CRO), announces the expansion of its preclinical contract research laboratory in St Paul, MN. The expansion of the laboratory provides additional capacity to increase the in vivo research...

2012-10-04 23:02:16

The porcine sciatica model can evaluate efficacy and PK/PD from the same subject and may provide more clinically relevant data at preclinical stages minimizing expensive failures. St Paul, MN (PRWEB) October 03, 2012 MD Biosciences has developed a large preclinical model of neuropathic pain for preclinical evaluation of analgesic or neuroprotective therapies. The sciatica model was developed in the pig, as the innervation is similar to that of humans, providing more clinically relevant data...

2008-11-11 12:00:26

MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its pre-clinical capabilities at the 2008 Neuroscience Conference in Washington, DC, November 15 - 19th, 2008, booth 1825. Capabilities included in the showcase are efficacy disease models within Multiple Sclerosis (MS), Gliosis, Parkinson's Disease, Nociceptive, Neuropathic and Inflammatory Pain. Multiple Sclerosis: Multiple sclerosis is a demyelinating disease of the CNS....

2008-09-15 18:00:37

MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its inflammations related pre-clinical services and research products at the 15th International Inflammation Research Association (IRA) Conference, September 21-24, Chantilly, VA. Capabilities featured will be pre-clinical efficacy disease models and research products for drug discovery and research. MD Biosciences will be hosting a lunch and learn session titled "Discovery of...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related